Phytoestrogens and their human metabolites show distinct agonistic and antagonistic properties on estrogen receptor α (ERα) and ERβ in human cells

Toxicological Sciences

Volumn 80, Issue 1, 2004, Pages 14-25

  Mueller, Stefan O ^a   Simon, Stephanie ^a   Chae, Kun ^b   Metzler, Manfred ^c   Korach, Kenneth S ^b  

^a MERCK KGAA   (Germany)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c UNIVERSITY OF KARLSRUHE   (Germany)

Author keywords

Coactivator recruitment; Endocrine disruptors; ER ; ER ; Ishikawa; Xenoestrogen

Indexed keywords

3',4',7 TRIHYDROXYISOFLAVONE; 4',6,7 TRIHYDROXYISOFLAVONE; 6 HYDROXYENTEROLACTONE; ANTIESTROGEN; COUMESTROL; DAIDZEIN; DIETHYLSTILBESTROL; DRUG METABOLITE; ENTEROLACTONE; EQUOL; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; GENISTEIN; ISOFLAVONE DERIVATIVE; PHYTOESTROGEN; RESVERATROL; STEROID RECEPTOR COACTIVATOR 1; UNCLASSIFIED DRUG; ZEARALENONE;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG CARCINOGENICITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ESTROGEN RESPONSIVE ELEMENT; HORMONAL REGULATION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; PROMOTER REGION; STRUCTURE ANALYSIS; TOXICITY TESTING; TRANSACTIVATION;

CELLS, CULTURED; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUORESCENCE POLARIZATION; HUMANS; LIGANDS; PHYTOESTROGENS;

EID: 3242798960     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/kfh147     Document Type: Article

References (52)

1. Adlercreutz, H. (1995). Phytoestrogens: Epidemiology and a possible role in cancer protection. Environ. Health Perspect. 103, 103-112.
2. Allred, C. D., Ju, Y. H., Allred, K. F., Chang, J., and Helferich, W. G. (2001). Dietary genistin stimulates growth of estrogen-dependent breast cancer tumors similar to that observed with genistein. Carcinogenesis 22, 1667-1673.
3. Almstrup, K., Fernandez, M. F., Petersen, J. H., Olea, N., Skakkebaek, N. E., and Leffers, H. (2002). Dual effects of phytoestrogens result in U-shaped dose-response curves. Environ. Health Perspect. 110, 743-748.
4. An, J. P., Tzagarakis-Foster, C., Scharschmidt, T. C., Lomri, N., and Leitman, D. C. (2001). Estrogen receptor β-selective transcriptional activity and recruitment of coregulators by phytoestrogens. J. Biol. Chem. 276, 17808-17814.
5. Basly, J. P., MarreFournier, F., LeBail, J. C., Habrioux, G., and Chulia, A. J. (2000). Estrogenic/antiestrogenic and scavenging properties of (E)- and (Z)-resveratrol. Life Sci. 66, 769-777.
6. Bhat, K. P., Lantvit, D., Christov, K., Mehta, R. G., Moon, R. C., and Pezzuto, J. M. (2001). Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res. 61, 7456-7463.
7. Bhat, K. P., and Pezzuto, J. M. (2001). Resveratrol exhibits cytostatic and anti-estrogenic properties with human endometrial adenocarcinoma (Ishikawa) cells. Cancer Res. 61, 6137-6144.
8. Bingham, S. A., Atkinson, C., Liggins, J., Bluck, L., and Coward, A. (1998). Phyto-oestrogens: Where are we now? Br. J. Nutr. 79, 393-406.
9. Bouker, K. B., and Hilakivi-Clarke, L. (2000). Genistein: Does it prevent or promote breast cancer? Environ. Health Perspect. 108, 701-708.
10. Bowers, J. L., Tyulmenkov, V. V., Jernigan, S. C., and Klinge, C. M. (2000). Resveratrol acts as a mixed agonist/antagonist for estrogen receptors α and β Endocrinology 141, 3657-3667.
11. Cappelletti, V., Fioravanti, L., Miodini, P., and Di Fronzo, G. (2000). Genistein blocks breast cancer cells in the G(2)M phase of the cell cycle. J. Cell. Biochem. 79, 594-600.
12. Cassidy, A. (1999). Potential tissue selectivity of dietary phytoestrogens and estrogens. Curr. Opin. Lipidol. 10, 47-52.
13. Cassidy, A., Hanley, B., and Lamuela-Raventos, R. M. (2000). Isoflavones, lignans, and stilbenes: Origins, metabolism, and potential importance to human health. J. Sci. Food Agric. 80, 1044-1062.
14. Cotroneo, M. S., Wang, J., Fritz, W. A., Eltoum, I. E., and Lamartiniere, C. A. (2002). Genistein action in the prepubertal mammary gland in a chemoprevention model. Carcinogenesis 23, 1467-1474.
15. Couse, J. F., Hewitt, S. C., Bunch, D. O., Sar, M., Walker, V. R., Davis, B. J., and Korach, K. S. (1999). Postnatal sex reversal of the ovaries in mice lacking estrogen receptors α and β. Science 286, 2328-2331.
16. Couse, J. F., and Korach, K. S. (1999). Estrogen receptor null mice: What have we learned and where will they lead us? Endocrine Rev. 20, 358-417.
17. Delclos, K. B., Bucci, T. J., Lomax, L. G., Latendresse, J. R., Warbritton, A., Weis, C. C., and Newbold, R. R. (2001). Effects of dietary genistein exposure during development on male and female CD (Sprague-Dawley) rats. Reprod. Toxicol. 15, 647-663.
18. Dong, Z. (2003). Molecular mechanism of the chemopreventive effect of resveratrol. Mutat. Res. 523-524, 145-150.
19. Grubbs, C. J., Farnell, D. R., Hill, D. L., and McDonough, K. C. (1985). Chemoprevention of N-nitroso-N-methylurea-induced mammary cancers by pretreatment with 17β-estradiol and progesterone. J. Natl. Cancer Inst. 74, 927-931.
20. Hall, J. M., Couse, J. F., and Korach, K. S. (2001). The multifaceted mechanisms of estradiol and estrogen receptor signaling. J. Biol. Chem. 276, 36869-36872.
21. Hall, J. M., and Korach, K. S. (2002). Analysis of the molecular mechanisms of human estrogen receptors α and β reveals differential specificity in target promoter regulation by xenoestrogens. J. Biol. Chem. 277, 44455-44461.
22. Hall, J. M., and McDonnell, D. P. (1999). The estrogen receptor β-isoform (ERβ) of the human estrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140, 5566-5578.
23. Hall, J. M., McDonnell, D. P., and Korach, K. S. (2002). Allosteric regulation of estrogen receptor structure, function, and coactivator recruitment by different estrogen response elements. Mol. Endocrinol. 16, 469-486.
24. Hilakivi-Clarke, L., Cho, E., Onojafe, I., Raygada, M., and Clarke, R. (1999a). Maternal exposure to genistein during pregnancy increases carcinogen-induced mammary tumorigenesis in female rat offspring. Oncol. Rep. 6, 1089-1095.
25. Hilakivi-Clarke, L., Onojafe, I., Raygada, M., Cho, E., Skaar, T., Russo, I., and Clarke, R. (1999b). Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis. Br. J. Cancer 80, 1682-1688.
26. Ignar-Trowbridge, D. M., Pimentel, M., Teng, C. T., Korach, K. S., and McLachlan, J. A. (1995). Cross talk between peptide growth factor and estrogen receptor signaling systems. Environ. Health Perspect. 7, 35-38.
27. Jacobs, E., Kulling, S. E., and Metzler, M. (1999). Novel metabolites of the mammalian lignans enterolactone and enterodiol in human urine. J. Steroid Biochem. Mol. Biol. 68, 211-218.
28. Jacobs, E., and Metzler, M. (1999). Oxidative metabolism of the mammalian lignans enterolactone and enterodiol by rat, pig, and human liver microsomes. J. Agric. Food Chem. 47, 1071-1077.
29. Jefferson, W. N., and Newbold, R. R. (2000). Potential endocrine-modulating effects of various phytoestrogens in the diet. Nutrition 16, 658-662.
30. Klinge, C. M. (2001). Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 29, 2905-2919.
31. Kuiper, G. G. J. M., Carlsson, B., Grandien, K., Enmark, E., Haggblad, J., Nilsson, S., and Gustafsson, J. (1997). Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors α and β. Endocrinology 138, 863-870.
32. Kuiper, G. G., Lemmen, J. G., Carlsson, B., Corton, J. C., Safe, S. H., van der Saag, P. T., van der Burg, B., and Gustafsson, J. A. (1998). Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 139, 4252-4263.
33. Liu, M. M., Albanese, C., Anderson, C. M., Hilty, K., Webb, P., Uht, R. M., Price, R. H., Pestell, R. G., and Kushner, P. J. (2002). Opposing action of estrogen receptors α and β on cyclin D1 gene expression. J. Biol. Chem. 277, 24353-24360.
34. Mazur, W., and Adlercreutz, H. (2000). Overview of naturally occurring endocrine-active substances in the human diet in relation to human health. Nutrition 16, 654-658.
35. Mueller, S. O. (2002). Overview of in vitro tools to assess the estrogenic and antiestrogenic activity of phytoestrogens. J. Chromatogr. B 777, 155-165.
36. Mueller, S. O., Hall, J. M., Swope, D. L., Pedersen, L. C., and Korach, K. S. (2003a). Molecular determinants of the stereoselectivity of agonist activity of estrogen receptors (ER) α and β. J. Biol. Chem. 278, 12255-12262.
37. Mueller, S. O., Kling, M., Arifin Firzani, P., Mecky, A., Duranti, E., Shields-Botella, J., Delansorne, R., Broschard, T., and Kramer, P.-J. (2003b). Activation of estrogen receptor [α] and ER[β] by 4-methylbenzylidene-camphor in human and rat cells: Comparison with phyto- and xenoestrogens. Toxicol. Lett. 142, 89-101.
38. Mueller, S. O., and Korach, K. S. (2001a). Estrogen receptors and endocrine diseases, lessons from estrogen receptor knockout mice. Curr. Opin. Pharmacol. 1, 613-619.
39. Mueller, S. O., and Korach, K. S. (2001b). Mechanisms of estrogen receptor-mediated agonistic and antagonistic effects. In Endocrine Disruptors (M. Metzler, Ed.), Vol. I, pp. 1-25. Springer, Berlin.
40. Munro, I.C., Harwood, M., Hlywka, J.J., Stephen, A.M., Doull, J., Flamm, W.G., and Adlercreutz, H. (2003). Soy isoflavones: A safety review. Nutr. Rev. 61, 1-33.
41. Murrill, W. B., Brown, N. B., Zhang, J.-X., Manzolillo, P. A., Barnes, S., and Lamartiniere, C. A. (1996). Prepubertal genistein exposure suppresses mammary cancer and enhances gland differentiation in rats. Carcinogenesis 17, 1451-1457.
42. Newbold, R. R., Banks, E. P., Bullock, B., and Jefferson, W. N. (2001). Uterine adenocarcinoma in mice treated neonatally with genistein. Cancer Res. 61, 4325-4328.
43. Niemeyer, H. B., Honig, D., Lange-Bohmer, A., Jacobs, E., Kulling, S. E., and Metzler, M. (2000). Oxidative metabolites of the mammalian lignans enterodiol and enterolactone in rat bile and urine. J. Agric. Food Chem. 48, 2910-2919.
44. Nishikawa, J., Saito, K., Goto, J., Dakeyama, F., Matsuo, M., and Nishihara, T. (1999). New screening methods for chemicals with hormonal activities using interaction of nuclear hormone receptor with coactivator. Toxicol. Appl. Pharmacol. 154, 76-83.
45. Norris, J. D., Fan, D. J., Wagner, B. L., and McDonnell, D. P. (1996). Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity. Mol. Endocrinol. 10, 1605-1616.
46. Norris, J. D., Fan, D., Kerner, S. A., and McDonnell, D. P. (1997). Identification of a third autonomous activation domain within the human estrogen receptor. Mol. Endocrinol. 11, 747-754.
47. Onate, S. A., Tsai, S. Y., Tsai, M. J., and O'Malley, B. W. (1995). Sequence and characterization of a coactivator for the steroid hormone receptor superfamily. Science 270, 1354-1357.
48. Paige, L. A., Christensen, D. J., Gron, H., Norris, J. D., Gottlin, E. B., Padilla, K. M., Chang, C. Y., Ballas, L. M., Hamilton, P. T., McDonnell, D. P., et al. (1999). Estrogen receptor (ER) modulators each induce distinct conformational changes in ERα and ERβ. Proc. Natl. Acad. Sci. USA 96, 3999-4004.
49. Routledge, E. J., White, R., Parker, M. G., and Sumpter, J. P. (2000). Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) α and ERβ. J. Biol. Chem. 275, 35986-35993.
50. Tremblay, G. B., and Giguere, V. (2002). Coregulators of estrogen receptor action. Crit. Rev. Eukaryot. Gene Expr. 12, 1-22.
51. Voegel, J., Heine, M., Zechel, C., Chambon, P., and Gronemeyer, H. (1996). TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. EMBO J. 15, 3667-3675.
52. Wakeling, A. E., and Bowler, J. (1992). ICI 182,780, a new antioestrogen with clinical potential. J. Steroid Biochem. Mol. Biol. 43, 173-177.